Next-Generation Sequencing Analysis on Image-Guided Biopsy Samples in Early-Stage Lung Cancer: Feasibility Study and Comparison With Surgical Samples

Introduction: Limited information exists on next-generation sequencing (NGS) success for lung tumors of 30 mm or less. We aimed to compare NGS success rates across biopsy techniques for these tumors, assess DNA sequencing quality, and verify reliability against surgical resection results. Methods: W...

Full description

Saved in:
Bibliographic Details
Main Authors: Louis Gros, MD, Rowena Yip, PhD, MPH, Arel Golombeck, MD, David F. Yankelevitz, MD, Claudia I. Henschke, PhD, MD
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:JTO Clinical and Research Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324001474
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841545498432897024
author Louis Gros, MD
Rowena Yip, PhD, MPH
Arel Golombeck, MD
David F. Yankelevitz, MD
Claudia I. Henschke, PhD, MD
author_facet Louis Gros, MD
Rowena Yip, PhD, MPH
Arel Golombeck, MD
David F. Yankelevitz, MD
Claudia I. Henschke, PhD, MD
author_sort Louis Gros, MD
collection DOAJ
description Introduction: Limited information exists on next-generation sequencing (NGS) success for lung tumors of 30 mm or less. We aimed to compare NGS success rates across biopsy techniques for these tumors, assess DNA sequencing quality, and verify reliability against surgical resection results. Methods: We used data from the Initiative for Early Lung Cancer Research on Treatment study, including patients with lung tumors measuring 30 mm or less who had surgery and NGS on biopsies since 2016. We collected data on biopsy type, nodule characteristics, complications, sequencing feasibility, clinical actionable variants, surgery type, and TNM classification. We compared NGS feasibility and quality between biopsy methods and, for those with NGS on surgical samples, compared feasibility, quality, and detection of actionable variants. Results: Among the 654 participants with lung tumors of 30 mm or less who underwent surgery, 70 had NGS on prior biopsies. The median age was 68.5; 51.4% were male individuals, and 75.7% were smokers. The mean diameter of biopsied nodules was 17.7 mm, with 67.1% fine-needle aspiration, 17.1% computed tomography–guided transthoracic core needle biopsies, and 17.1% endobronchial ultrasound–guided transbronchial needle aspiration. DNA sequencing was feasible in 97.1% of biopsy samples; 2.9% had low tumor cellularity. Coverage depth was achieved in 89.7% of biopsies. RNA sequencing was successful in 66.2% of biopsies, especially in core needle biopsies. Actionable alterations were found in 41.4% of patients. Among the participants, 30% had NGS on surgical samples. RNA sequencing was more feasible on surgical samples (95.2% versus 42.9% for biopsies). NGS on surgical samples matched biopsy results in 90% of patients, with 10% showing additional alterations. Conclusion: DNA sequencing succeeded in 97.1% of biopsies of nodules 30 mm or less, whereas RNA sequencing feasibility was lower. NGS on biopsy samples is generally reliable but requires careful review.
format Article
id doaj-art-458622b86ef44447bca83d4ed5b1cee4
institution Kabale University
issn 2666-3643
language English
publishDate 2025-02-01
publisher Elsevier
record_format Article
series JTO Clinical and Research Reports
spelling doaj-art-458622b86ef44447bca83d4ed5b1cee42025-01-12T05:25:48ZengElsevierJTO Clinical and Research Reports2666-36432025-02-0162100777Next-Generation Sequencing Analysis on Image-Guided Biopsy Samples in Early-Stage Lung Cancer: Feasibility Study and Comparison With Surgical SamplesLouis Gros, MD0Rowena Yip, PhD, MPH1Arel Golombeck, MD2David F. Yankelevitz, MD3Claudia I. Henschke, PhD, MD4Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New YorkDepartment of Radiology, Icahn School of Medicine at Mount Sinai, New York, New YorkDepartment of Radiology, Icahn School of Medicine at Mount Sinai, New York, New YorkDepartment of Radiology, Icahn School of Medicine at Mount Sinai, New York, New YorkCorresponding author. Address for correspondence: Claudia I. Henschke, PhD, MD, Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029.; Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New YorkIntroduction: Limited information exists on next-generation sequencing (NGS) success for lung tumors of 30 mm or less. We aimed to compare NGS success rates across biopsy techniques for these tumors, assess DNA sequencing quality, and verify reliability against surgical resection results. Methods: We used data from the Initiative for Early Lung Cancer Research on Treatment study, including patients with lung tumors measuring 30 mm or less who had surgery and NGS on biopsies since 2016. We collected data on biopsy type, nodule characteristics, complications, sequencing feasibility, clinical actionable variants, surgery type, and TNM classification. We compared NGS feasibility and quality between biopsy methods and, for those with NGS on surgical samples, compared feasibility, quality, and detection of actionable variants. Results: Among the 654 participants with lung tumors of 30 mm or less who underwent surgery, 70 had NGS on prior biopsies. The median age was 68.5; 51.4% were male individuals, and 75.7% were smokers. The mean diameter of biopsied nodules was 17.7 mm, with 67.1% fine-needle aspiration, 17.1% computed tomography–guided transthoracic core needle biopsies, and 17.1% endobronchial ultrasound–guided transbronchial needle aspiration. DNA sequencing was feasible in 97.1% of biopsy samples; 2.9% had low tumor cellularity. Coverage depth was achieved in 89.7% of biopsies. RNA sequencing was successful in 66.2% of biopsies, especially in core needle biopsies. Actionable alterations were found in 41.4% of patients. Among the participants, 30% had NGS on surgical samples. RNA sequencing was more feasible on surgical samples (95.2% versus 42.9% for biopsies). NGS on surgical samples matched biopsy results in 90% of patients, with 10% showing additional alterations. Conclusion: DNA sequencing succeeded in 97.1% of biopsies of nodules 30 mm or less, whereas RNA sequencing feasibility was lower. NGS on biopsy samples is generally reliable but requires careful review.http://www.sciencedirect.com/science/article/pii/S2666364324001474NGS feasibilityEarly-stage lung cancerStage IFine needle aspirationCore needle biopsyEBUS-TBNA
spellingShingle Louis Gros, MD
Rowena Yip, PhD, MPH
Arel Golombeck, MD
David F. Yankelevitz, MD
Claudia I. Henschke, PhD, MD
Next-Generation Sequencing Analysis on Image-Guided Biopsy Samples in Early-Stage Lung Cancer: Feasibility Study and Comparison With Surgical Samples
JTO Clinical and Research Reports
NGS feasibility
Early-stage lung cancer
Stage I
Fine needle aspiration
Core needle biopsy
EBUS-TBNA
title Next-Generation Sequencing Analysis on Image-Guided Biopsy Samples in Early-Stage Lung Cancer: Feasibility Study and Comparison With Surgical Samples
title_full Next-Generation Sequencing Analysis on Image-Guided Biopsy Samples in Early-Stage Lung Cancer: Feasibility Study and Comparison With Surgical Samples
title_fullStr Next-Generation Sequencing Analysis on Image-Guided Biopsy Samples in Early-Stage Lung Cancer: Feasibility Study and Comparison With Surgical Samples
title_full_unstemmed Next-Generation Sequencing Analysis on Image-Guided Biopsy Samples in Early-Stage Lung Cancer: Feasibility Study and Comparison With Surgical Samples
title_short Next-Generation Sequencing Analysis on Image-Guided Biopsy Samples in Early-Stage Lung Cancer: Feasibility Study and Comparison With Surgical Samples
title_sort next generation sequencing analysis on image guided biopsy samples in early stage lung cancer feasibility study and comparison with surgical samples
topic NGS feasibility
Early-stage lung cancer
Stage I
Fine needle aspiration
Core needle biopsy
EBUS-TBNA
url http://www.sciencedirect.com/science/article/pii/S2666364324001474
work_keys_str_mv AT louisgrosmd nextgenerationsequencinganalysisonimageguidedbiopsysamplesinearlystagelungcancerfeasibilitystudyandcomparisonwithsurgicalsamples
AT rowenayipphdmph nextgenerationsequencinganalysisonimageguidedbiopsysamplesinearlystagelungcancerfeasibilitystudyandcomparisonwithsurgicalsamples
AT arelgolombeckmd nextgenerationsequencinganalysisonimageguidedbiopsysamplesinearlystagelungcancerfeasibilitystudyandcomparisonwithsurgicalsamples
AT davidfyankelevitzmd nextgenerationsequencinganalysisonimageguidedbiopsysamplesinearlystagelungcancerfeasibilitystudyandcomparisonwithsurgicalsamples
AT claudiaihenschkephdmd nextgenerationsequencinganalysisonimageguidedbiopsysamplesinearlystagelungcancerfeasibilitystudyandcomparisonwithsurgicalsamples